The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 483.76% and ...

As in years past, wine and digestive health was a popular topic in 2024. We considered the effects of low-sulfur wines and ...

The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

I’m wondering if any studies explain this and what’s the best way to address it. Should I increase the dose further or switch ...

Wegovy and Ozempic are the exact same drug: semaglutide. They are dosed slightly differently and marketed for different ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.